Ligand id: 9043

Name: apalutamide

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 121.42
Molecular weight 477.09
XLogP 3.78
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Apalutamide (using research codes ARN-509 and JNJ-56021927) was evaluated in several Phase 3 clinical trials in prostate cancer patients. As a result of positive clinical outcomes (see NCT01946204 results in Smith et al. (2018) [3]), the US FDA approved use of apalutamide for the treatment of non-metastatic castration-resistant prostate cancer in February 2018. Click here to link to ClinicalTrials.gov's list of current Phase 3 apalutamide trials.